RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

Brufsky, Adam; Bondarenko, Igor; Yu. Smirnov, V.; A. Hurvitz, Sara; A. Perez, Edith; Ponomarova, Olga; Vynnychenko, Ihor; Swamy, Raji; Mu, Hua; Rivera, Ragene

doi:10.1158/0008-5472.sabcs-09-42

Public

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

Published in Cancer Research • Dec 1, 2009

Authors:

Adam Brufsky

Igor Bondarenko

V. Yu. Smirnov

Abstract

Abstract Background: Three prior Phase III trials (E2100, AVADO, and RIBBON-1) established the clinical benefit of adding bevacizumab (BV) to various chemotherapies (chemos) as first-line treatment for metastatic breast cancer (MBC). A previous Phase III study (AVF2119g) in patients with predominant...

Subject

Medicine

Metastatic breast cancer

Docetaxel

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!